Skip to Content

Mateon Therapeutics Inc MATN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Mateon Therapeutics Inc is an oncology company focusing on therapies against cancers and infectious diseases. It has three business segments namely, PointR; Mateon/Oxigene; and Oncotelic. PointR is the developer of vision grid/cluster computing/AI to support drug development. Mateon/Oxigene develops a Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma and OXi4503 rare pediatric designation for pediatric ALL. Oncotelic consists development of OT-101 - antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 against pancreatic cancer, glioblastoma, and melanoma. The firm is also developing Artemisinin which is approved by India and in phase 4 clinical trial against COVID.

Contact
29397 Agoura Road, Suite 107
Agoura Hills, CA, 91301
T +1 650 635-7000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Slow Growth
Employees 13